Drug intelligence / Profile preview

TTX334e

Development stage: Unknown
Lead developer: Temple Therapeutics
Modality: Small Molecules
Administration: Unknown

Overview

TTX334e is a small molecule drug under development for the treatment of endometriosis. It is being developed by Temple Therapeutics and represents an innovative approach distinct from current therapies such as painkillers, hormonal treatments, or surgery. As of 2025, the drug remains in early clinical development (preclinical to Phase 1), with its primary indication being endometriosis. The precise mechanism of action has not been publicly disclosed.

Beyond the preview

Go deeper on TTX334e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TTX334e.

Explore the full profile